Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Cervical Cancer
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087126
- Testing
- topotecan hydrochloride
- Where
- 27 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gynecologic Oncology Group
Squamous Cell Carcinoma of the Head and Neck
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Protocol VRXP-A106 will enroll patients with Stage II-IVA head and neck cancer patients who will be treated with surgical resection.
- Trial name
- NCT02124850
- Testing
- Motolimod, Cetuximab, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Celgene
Head and Neck Cancer
PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer
Historically metastatic squamous cell carcinoma in a cervical lymph node from an occult primary malignancy of the head and neck was evaluated with panendoscopy and biopsies of high risk areas, such as the base of tongue…
- Trial name
- NCT00656760
- Testing
- PET/CT
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Esophageal Squamous Cell Carcinoma
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens
- Trial name
- NCT03797625
- Testing
- Irinotecan, DDP, Endostar
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06662058
- Testing
- Audiometric Test, Interview
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Emory University
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
The goal of this clinical trial is to evaluate if adding chemotherapy and immunotherapy as induction treatment prior to definitive chemoradiotherapy could improve the outcomes of locally advanced HPV-negative head and neck…
- Trial name
- NCT07776340
- Testing
- Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Squamous Cell Carcinoma of Head and Neck
Concurent Chemoradiotherapy in Head and Neck Cancers
To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\m2) for…
- Trial name
- NCT04780750
- Testing
- Docetaxel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Tongue Cancer, Squamous Cell Carcinoma
Surgical Margin Assessment by 3D Ultrasound
Complete removal of cancer encircled by a secure margin of healthy tissue is the aim of surgical oncology. A close or positive surgical margin reported by pathologist typically ends in adjuvant therapies (re-surgery and/or…
- Conditions
- Tongue Cancer, Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT05740774
- Testing
- 3D ultrasound
- Where
- Denmark
- Volunteers
- 7 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Head and Neck Cancer
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
The purpose of this study is to find out whether adding ZD1839 to standard treatment (Cisplatin and Radiation Therapy) of unresectable head and neck cancers is better than cisplatin and radiation alone.
- Trial name
- NCT00195078
- Testing
- ZD1839 (IRESSA), Cisplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Weill Medical College of Cornell University
Head and Neck Cancer (H&N)
Screening Psychosocial Distress in Head and Neck Cancer
This prospective, multicenter study aims to assess the presence of psychosocial distress using the Distress Thermometer in patients treated for head and neck cancer at the initiation of their speech-language therapy.
- Trial name
- DEP-VADS-ORTHO (NCT07851818)
- Testing
- Psychosocial distress screening using the Distress Thermometer
- Volunteers
- 80 people
- Sponsor
- Hôpital NOVO
Squamous Cell Carcinoma of the Head and Neck
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
A small group of skin cancers of the head and neck, called resected cutaneous squamous carcinomas, are more aggressive than most cancers of this type, even after being treated with standard therapy.
- Trial name
- NCT03057613
- Testing
- Pembrolizumab, IMRT 60-66Gy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Case Comprehensive Cancer Center
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
This phase II/III trial studies how well a reduced dose of radiation therapy works with nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer that is early in its…
- Conditions
- Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT03952585
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- 494 sites in United States, Canada
- Volunteers
- 384 people
- Sponsor
- National Cancer Institute (NCI)
Oral Cavity Squamous Cell Carcinoma
Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction
- Trial name
- NeoNivo (NCT03843515)
- Testing
- Nivolumab
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Amsterdam UMC, location VUmc
Esophageal Neoplasms, Esophageal Diseases
Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with resectable esophageal squamous cell carcinoma
- Trial name
- NCT03200691
- Testing
- 3-DCRT or IMRT radiation, anti-PD-1 antibody SHR-1210
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Hangzhou Cancer Hospital
Recurrent Head and Neck Squamous Cell Carcinoma
Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to determine whether a perioperative PD-1 antibody-based treatment strategy, consisting of neoadjuvant PD-1 antibody plus chemotherapy followed by adjuvant PD-1 antibody after surgery, improves…
- Trial name
- neo-Recur (NCT07751289)
- Testing
- Neoadjuvant PD-1 antibody plus chemotherapy, surgery, Adjuvant PD-1 antibody
- Volunteers
- 217 people
- Sponsor
- Yanjie Zhang, MD
Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02677597
- Testing
- Cisplatin Combined With S-1, Cisplatin Combined With Paclitaxel
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
- Trial name
- NCT05426850
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Head and Neck Cancer
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
The goal of this clinical research study is to learn if giving the new drug, Tarceva® (OSI-774), in combination with Platinol® (cisplatin) and Taxotere® (docetaxel) is effective in the treatment of metastatic or recurrent head…
- Trial name
- NCT00076310
- Testing
- Docetaxel, OSI-774, Cisplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Head and Neck
Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN
The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.
- Trial name
- NCT03880396
- Testing
- hypofractionated Rth with platinol
- Where
- Egypt
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.